GenVivo, Inc.
Marco Medrano is a Process Engineer with experience in developing in vitro models of human skeletal muscle, biomaterial surface functionalization, and analyzing cell morphology and differentiation. Previously, Marco worked as a Computational Chemistry Undergraduate Researcher and a Bioengineering Undergraduate Researcher, investigating amyloid beta 42 peptide dynamics and CRISPR-Cas9 structure. Marco holds a Master of Science in Bioengineering and Biomedical Engineering and a Bachelor of Science in Bioengineering and Biomedical Engineering.
GenVivo, Inc.
GenVivo was founded on the idea that we can effectively treat cancer patients with the latest gene delivery technologies. We are committed to enhancing the overall patient treatment experience. We deliver innovative drugs to empower the patient’s own immune system to mount a targeted attack against cancer. These therapies are off-the-shelf and come without the cost and time delays associated with personalized cancer vaccines. We are dedicated to providing accessible and efficient solutions that redefine the landscape of cancer treatment.